hackint0sh/New-Dataset huggingface dataset:
Oral lactate administration improves/lowers glucose excursions following an oral glucose tolerance test (OGTT) by stimulating insulin secretion and delaying glucose absorption. conditions: PreDiabetes conditions: Metabolic Syndrome conditions: Insulin Resistance studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: In a randomized, double-blinded, placebo-controlled crossover trial, we will investigate the effect of addition of 25 g lactate vs. placebo to an OGTT on two trial days separated by a minimum of fourteen days and a maximum of one month. We will include 12 individuals with pre-diabetes \[9\], having HbA1c 39-47 mmol/L and being above 40 years of age. primaryPurpose: BASIC_SCIENCE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 12 type: ESTIMATED name: Lactate name: Placebo measure: Difference in integrated glucose concentrations between CTR and LAC following an OGTT measure: Difference in glucose absorption measure: Difference in insulin sensitivity measure: Difference in insulin secretion measure: Difference in free fatty acids concentration measure: Difference in ventricular emptying rate measure: Difference in subjective appetite sensation measure: Difference in integrated GLP-1 concentrations sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06265324 id: Soh-Med-23-12-04MD briefTitle: Drug-coated Balloon Treatment in Coronary Lesions overallStatus: NOT_YET_RECRUITING date: 2024-02-10 date: 2024-06-10 date: 2025-02-10 date: 2024-02-20 date: 2024-02-20 name: Sohag University class: OTHER briefSummary: This study is multicenter registry for drug-coated balloon treatment for de novo and in-stent restenosis lesions conditions: Drug-coated Balloon studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Angioplasty measure: Major adverse cardiac events at 6 months sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Sohag faculty of medicine city: Sohag country: Egypt name: Sharaf Eldin Shazly, PHD role: CONTACT phone: 0112 9999792 name: Imran Saber, MA role: PRINCIPAL_INVESTIGATOR lat: 26.55695 lon: 31.69478 hasResults: False
nctId: NCT06265311 id: 20221307-2 briefTitle: IDUS in CBD Stone Recurrence High Risk Patients overallStatus: RECRUITING date: 2021-11-02 date: 2024-01-31 date: 2024-06 date: 2024-02-20 date: 2024-04-19 name: Shanghai Municipal Hospital of Traditional Chinese Medicine class: OTHER briefSummary: This study is designed to observed CBD stones cases with high recurrence risks applying IDUS or not during ERCP.
Symptoms and conditions after ERCP were also followed up including blood amylase, routine blood test, abdominal pain, post-ERCP pancreatitis, resection of gallbladder, recurrence of CBD stone and onset of cholangitis. conditions: Choledocholithiasis conditions: Cholangiopancreatography, Endoscopic Retrograde conditions: Ultrasonography studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 80 type: ESTIMATED name: IDUS examination measure: recurrence of bile duct stone or cholangitis measure: need for a nasobiliary tube measure: need for stents measure: operation time measure: radiation time measure: hospitalization cost measure: Questionnaire of Symptoms and conditions after ERCP measure: White blood cell count measure: Red blood cell count measure: Platelet count measure: total bilirubin, direct bilirubin measure: Liver function test (ALT, AST) measure: albumin measure: total protein measure: Gamma-glutamyl transferase (GGT) test measure: An alkaline phosphatase (ALP) test measure: whether have a resection of gallbladder checklist sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shang General Hospital status: RECRUITING city: Shanghai zip: 200080 country: China name: Hang Zhao role: CONTACT phone: 18621186288 email: drzhaohang@163.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06265298 id: RECHMPL23_0099 briefTitle: Implementation of a Protocol for the Transdifferentiation of Buccal Mucosal Epithelium Into Corneal Epithelium acronym: TransBuCor overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2025-02 date: 2025-02 date: 2024-02-20 date: 2024-02-20 name: University Hospital, Montpellier class: OTHER name: Institute for Neuroscience Montpellier briefSummary: Objectives The transparent surface of the eye, called the cornea, plays a crucial role in transmitting light to the retina and in protecting the eye. On its external surface, the cornea is composed of a constantly renewing multistratified epithelium. This mechanism is fueled by stem cells located in the limbus (the transition zone between the cornea and the sclera). Limbal Stem Cell Deficiency (LSCD) is characterized by a decrease or cessation of epithelial renewal and neovascularization of the cornea. Consequently, the cornea loses its integrity and transparency. This visually impairing condition is currently in a therapeutic impasse as only autologous limbal or allogeneic corneal grafts are viable options, but they pose significant risks to patients.
Methodology This prospective monocentric study will be conducted on patients from the ophthalmology department of the Montpellier University Hospital who have an indication for conjunctival reconstruction. After obtaining consent from the patients, cells from the oral wall will be sent to the tissue bank of the Montpellier University Hospital, where they will be cultured. Finally, the transdifferentiation steps will be analyzed by the "Eye" research team at the Institute of Neuroscience in Montpellier, which is collaborating on the project. The investigators have established objective factors to assess the success of the developed protocol based on the literature : (i) \> 3% of stem cells in primary cultures, (ii) \<10% aborted colonies, (iii) Expression of LSC markers (Pax6, Krt14, p63). conditions: Limbal Stem Cell Deficiency studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: transversal and fondamental study primaryPurpose: OTHER masking: NONE count: 4 type: ESTIMATED name: Conjunctival reconstruction measure: Successful Transdifferentiation measure: Successful Transdifferentiation measure: Successful Transdifferentiation measure: Successful Transdifferentiation measure: Successful Transdifferentiation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU Gui de Chauliac - Service d'Ophtamologie city: Montpellier state: Occitanie zip: 34295 country: France name: Vincent DAIEN, Pr role: CONTACT email: v-daien@chu-montpellier.fr name: Vincent Daien, Pr role: PRINCIPAL_INVESTIGATOR lat: 43.61092 lon: 3.87723 hasResults: False
nctId: NCT06265272 id: 2022P002594 briefTitle: Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis overallStatus: RECRUITING date: 2023-12-10 date: 2026-12-19 date: 2026-12-19 date: 2024-02-20 date: 2024-02-20 name: Massachusetts General Hospital class: OTHER briefSummary: A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET/MRI acquisition protocols.
* Ga-PSMA PET/MRI may improve noninvasive and reproducible qualitative and quantitative assessment of liver function, structure, nodules and predict evolution of cirrhosis conditions: Liver Cirrhosis conditions: Hepatic Cell Carcinoma conditions: Portal Hypertension studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 45 type: ESTIMATED name: Injection of a gadolinium contrast agen name: Radiotracer Injection name: Imaging measure: Assessment of LI-RADS with Ga-PSMA-PET/MRI measure: Quantification of Macro- and Microperfusion in Cirrhotic Liver with Ga-PSMA-PET/MRI measure: Quantification of liver fibrosis with Ga-PSMA-PET/MRI vs. MRI and stand-alone PET measure: PET/MR protocol in liver cirrhosis sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School status: RECRUITING city: Charlestown state: Massachusetts zip: 02129 country: United States name: Onforio Catalano, MD, Ph.D role: CONTACT phone: 617-724-4030 email: ocatalano@mgh.harvard.edu name: Diandrea Galloway role: CONTACT phone: 617-643-1407 email: dgalloway@mgh.harvard.edu lat: 42.37787 lon: -71.062 hasResults: False
nctId: NCT06265259 id: 31-05-2023/25481 briefTitle: Efficacy of the Use of Vasopressin as a Primary Vasoconstrictor in Critically Ill Patients overallStatus: RECRUITING date: 2023-12-15 date: 2025-12-31 date: 2026-01-31 date: 2024-02-20 date: 2024-03-06 name: University of Thessaly class: OTHER briefSummary: Current guidelines recommend the inititaion of noradrenaline and if shock is refractory, then vasopressin should be administered. Data indicate that the earlier use of vasopressin may improve survival. Two large randomized controlled trial failed to prove a survival benefit from the early use of vasopressin. The present study will investigate the effect of an early initiation protocol of vasopressin (as the first vasoconstrictor drug) on the degree of multiorgan failure improvement and also on the course of sepsis (if in septic patients) versus early initiation of noradrenaline as first vasoconstrictor drug in hemodynamically unstable patients. conditions: Circulatory Shock studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 145 type: ESTIMATED name: Initiation of vasopressine as a first vasoconstrictive drug name: Initiation of noradrenaline as a first vasoconstrictive drug measure: Multiorgan failure improvement assessment measure: Sepsis course measure: Sepsis course measure: Sepsis course measure: Duration of administration of vasoconstrictors measure: laboratory tests measure: laboratory tests measure: laboratory tests measure: laboratory tests measure: laboratory tests measure: laboratory tests measure: laboratory tests measure: laboratory tests measure: laboratory tests measure: laboratory tests measure: laboratory tests measure: Cardiac enzymes measure: Cardiac enzymes measure: renal function measure: renal function measure: renal function measure: Mechanical ventilation duration measure: length of ICU stay measure: 28 day mortality measure: ICU mortality measure: Adverse events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: General University Hospital of Larissa, Intensive Care Unit status: RECRUITING city: Larissa state: Thessaly zip: 41110 country: Greece name: Vasiliki Tsolaki role: CONTACT phone: 00306972804419 email: vasotsolaki@yahoo.com name: Epaminondas Zakynthinos, Prof role: CONTACT phone: 00302413501280 email: ezakynth@yahoo.com name: Vasiliki TSOLAKI, MD, PhD role: SUB_INVESTIGATOR name: Asimina Valsamaki, MD, Msc role: SUB_INVESTIGATOR name: Epaminondas Zakynthinos, Prof role: PRINCIPAL_INVESTIGATOR lat: 39.63689 lon: 22.41761 hasResults: False
nctId: NCT06265246 id: 104993 briefTitle: Impact of Milk and Yogurt Supplementation on Bone Health, Body Composition, and Gut Microbiota in Canadian Young Adults overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-05-01 date: 2028-05-15 date: 2024-02-20 date: 2024-02-20 name: University of Saskatchewan class: OTHER name: Dairy Farmers of Canada name: Agriculture and Agri-Food Canada briefSummary: Milk and dairy products contain significant amounts of nutrients that contribute to optimal health - nutrients like calcium, vitamin D, and high-quality protein. Fermented milk products or fermented dairy products are dairy foods that have been fermented with certain bacteria. Yogurt is a fermented dairy product containing millions of beneficial bacteria. In this study, the invesgitagtors will look at the effect of milk (a non-fermented dairy product) and yogurt (a fermented dairy product) supplementation on bone health and the amount of fat and muscle mass in Canadian young adults over a 24-month period. While dairy products contain significant amounts of nutrients, the scientific community does not know the impact of long-term supplementation of fermented (i.e., yogurt) or non-fermented (i.e., milk) dairy food on bone health and the amount of fat and muscle mass in young adults. To fill this knowledge gap, the investigators will recruit participants with low calcium intake and assign them to three different groups: 1) milk (intervention) group; 2) yogurt (intervention) group; and 3) control group. The investigators will ask the participants in the milk group to drink 1.5 servings (375 mL) of milk per day for 24 months. Participants in the yogurt group will consume 2 servings (350 g) of yogurt per day for 24 months. Those in the control group will continue their usual diets. Using a randomized controlled trial design, the investigators will measure bone health parameters, hormonal indices related to bone metabolism, body composition (e.g., muscle mass, fat mass), and the number and composition of bacteria living in the gastrointestinal (GI) tract. The hypothesis is that supplementation with yogurt will have more positive effects on bone health indices, particularly femoral neck BMD as the primary outcome, than milk in Canadian adults aged 19-30 years. The secondary hypothesis is that supplementation with yogurt, as a fermented milk product, will have a more beneficial effect than milk on body composition measures. The data will provide valuable information for developing targeted health initiatives and marketing strategies regarding the benefits of fermented and non-fermented dairy product consumption. conditions: Osteoporosis conditions: Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: In this 24-month randomized controlled trial, the investigators will follow the Consolidated Standards of Reporting Trials (CONSORT) guidelines. Ninety-nine free-living adults aged 19-30 years with low dietary calcium intake will be randomly assigned to one of the following three intervention arms.
3. Habitual diet + 2 servings of yogurt providing approx. 500 mg Ca/day (either 1% fat plain yogurt, 2% fat plain yogurt, 1% fat flavoured yogurt, 2% fat flavoured yogurt) (n=33) primaryPurpose: PREVENTION masking: NONE count: 99 type: ESTIMATED name: Habitual Diet + Milk name: Habitual Diet + Yogurt measure: Femoral neck bone mineral density measure: Bone mineral density (total hip, lumbar spine, whole body) measure: Bone mineral content (total hip, femoral neck, lumbar spine, whole body) measure: Bone structure measure: Bone geometry measure: Serum bone alkaline phosphatase (biochemical indices of bone turnover) measure: Serum osteocalcin (biochemical indices of bone turnover) measure: Serum procollagen type 1 N-propeptide (biochemical indices of bone turnover) measure: Serum N-terminal telopeptide of type 1 collagen (biochemical indices of bone turnover) measure: Serum C-terminal telopeptide of type 1 collagen (biochemical indices of bone turnover) measure: Serum PTH (hormonal indices related to bone metabolism) measure: Serum 25(OH)D (hormonal indices related to bone metabolism) measure: Serum IGF-1 (hormonal indices related to bone metabolism) measure: Saliva IGF-1 (hormonal indices related to bone metabolism) measure: Fat mass and lean mass measure: Height measure: Weight measure: Gut microbiota via general lactobacillus and bifdobacterium measure: Dietary assessment measure: Physical activity sex: ALL minimumAge: 19 Years maximumAge: 30 Years stdAges: ADULT hasResults: False
nctId: NCT06265233 id: 69668 briefTitle: ERP Plus Improv Group Therapy for OCD (IMPROVE Study) overallStatus: RECRUITING date: 2024-02-09 date: 2025-01 date: 2025-01 date: 2024-02-20 date: 2024-02-22 name: Stanford University class: OTHER briefSummary: The goal of this study is to pilot test a novel group therapy intervention for adults with OCD. conditions: Obsessive-Compulsive Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Group Improv sessions name: Group Exposure and Response Prevention (ERP) Therapy measure: Change in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS) measure: Change in Intolerance of Uncertainty Score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: 401 Quarry status: RECRUITING city: Stanford state: California zip: 94304 country: United States name: Study Team role: CONTACT phone: 650-723-4095 email: ocdresearch@stanford.edu lat: 37.42411 lon: -122.16608 hasResults: False
nctId: NCT06265220 id: AB-101-03 briefTitle: AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis overallStatus: RECRUITING date: 2024-02-24 date: 2026-10 date: 2026-10 date: 2024-02-20 date: 2024-02-20 name: Artiva Biotherapeutics, Inc. class: INDUSTRY briefSummary: AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that is known to enhance the effect of monoclonal antibody therapies.
Patients may receive up to 2 cycles of treatment spaced 24 weeks apart. conditions: Lupus Nephritis - WHO Class III conditions: Lupus Nephritis - WHO Class IV studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: AB-101 name: Cyclophosphamide name: Fludarabine name: Rituximab measure: Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events measure: AB-101 Clinical Activity sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of California, San Diego status: RECRUITING city: San Diego state: California zip: 92121 country: United States name: Bosco Trinh role: CONTACT name: Bethany Karl, DO role: PRINCIPAL_INVESTIGATOR lat: 32.71533 lon: -117.15726 hasResults: False
nctId: NCT06265207 id: ArdahanU-Simsekli-DS-02 briefTitle: The Effect of Virtual Reality on Pain, Anxiety and Satisfaction Level Before Mammography overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-03-15 date: 2025-04-15 date: 2024-02-20 date: 2024-02-20 name: Ardahan University class: OTHER name: Kafkas University briefSummary: In this study, it is planned to determine the effect of virtual reality applied to women before mammography on pain, anxiety and satisfaction levels. For this purpose, individuals applying for breast cancer screening will first be randomly divided into experimental and control groups. Pain, anxiety and satisfaction level evaluation forms will be applied to the experimental group before the mammography procedure. A relaxing video will be watched with virtual reality glasses and the mammography will be performed. At the end of the mammography, the relevant forms will be applied to the individuals again. The control group will not be subjected to any additional application that will continue with the applied routine. conditions: Mammography conditions: Early Diagnosis of Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Single Blind Parallel Group Randomized Controlled Trial primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE maskingDescription: Since the researcher will be conducting the research, blinding will not be possible, and separate consent forms were prepared for the experimental and control groups, without specifying which group they were in, and it was planned to blind the participants in this way. In addition, in order to prevent statistical bias, it is planned to prevent bias in data analysis by coding the data as first group and second group, rather than experimental and control group, when entering the data into SPSS, and by not giving information about which group is the experiment and which is the control group. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 78 type: ESTIMATED name: Virtual reality name: routine maintenance measure: Visual Comparison Scale measure: State Anxiety Inventory measure: Satisfaction Evaluation Scale sex: FEMALE minimumAge: 18 Years maximumAge: 69 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06265194 id: ZAT2024 briefTitle: Effect of EMDR in the Treatment of Fibromyalgia acronym: EMDR overallStatus: COMPLETED date: 2015-01-01 date: 2018-01-01 date: 2018-03 date: 2024-02-20 date: 2024-02-20 name: Academy of Therapeutic Sciences, Turkey class: OTHER briefSummary: The goal of this randomized-controlled study is to investigate the impact of EMDR therapy on fibromyalgia symptoms, depression, sleep quality, and traumatic stress in fibromyalgia patients.
* Does EMDR therapy decrease depression, sleep quality and traumatic stress symptoms of individuals with fibromyalgia? conditions: Fibromyalgia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Eligible participants were randomized into two groups: one receiving TAU treatment (control group) and the other receiving both TAU and EMDR (experimental group). primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Participants do not have the knowledge of group interventions. whoMasked: PARTICIPANT count: 79 type: ACTUAL name: EMDR name: TAU measure: Fibromyalgia Impact Questionnaire (FIQ) measure: Pittsburgh Sleep Quality Index (PSQI) measure: Trauma Symptom Checklist-40 (TSC-40) measure: Beck Depression Inventory (BDI) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06265181 id: AIBU-SBF-SK-04 briefTitle: The Effect of Diabetes Coaching on Distress and Diabetes Self-Management overallStatus: NOT_YET_RECRUITING date: 2024-03-27 date: 2026-12-31 date: 2027-12-31 date: 2024-02-20 date: 2024-02-20 name: Abant Izzet Baysal University class: OTHER briefSummary: This research is a randomized controlled, experimental study planned to evaluate the effect of diabetes coaching on diabetes self-management, glycosylated hemoglobin and diabetes distress levels in individuals with type 2 diabetes.